Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 427,512
  • Shares Outstanding, K 119,084
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,780 K
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 23.42
Trade HUMA with:

Options Overview Details

View History
  • Implied Volatility 142.44% ( +15.23%)
  • Historical Volatility 71.99%
  • IV Percentile 91%
  • IV Rank 43.90%
  • IV High 305.42% on 06/30/23
  • IV Low 14.89% on 12/06/23
  • Put/Call Vol Ratio 0.23
  • Today's Volume 3,341
  • Volume Avg (30-Day) 735
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 15,902
  • Open Int (30-Day) 10,811

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +26.52%
on 04/12/24
4.11 -13.50%
on 04/19/24
+0.07 (+1.87%)
since 03/19/24
3-Month
2.69 +32.21%
on 01/22/24
4.86 -26.82%
on 02/20/24
+0.89 (+33.15%)
since 01/19/24
52-Week
1.96 +81.39%
on 11/01/23
5.60 -36.51%
on 05/08/23
+0.21 (+6.13%)
since 04/19/23

Most Recent Stories

More News
U.S. Senator Tommy Tuberville Just Reported a Purchase of $HUMA stock

In a new disclosure filed today, U.S. Senator Tommy Tuberville reported the purchase of $1,001 - $15,000 of Humacyte Inc, in a trade that took place on March 21. Since that trade was made, the stock has...

HUMA : 3.60 (+0.28%)
Fed Speaks, Canada Inflation on Lineup Next Week

Monday U.S. Economic Lookahead Home builder confidence index (Feb.) Featured Earnings ...

AOT.TO : 0.79 (-1.25%)
FLOW.TO : 0.1850 (-2.63%)
SMT.TO : 0.82 (unch)
DD : 73.67 (+0.19%)
CNM : 53.92 (-1.23%)
HQY : 80.80 (+1.19%)
HUMA : 3.60 (+0.28%)
BRNS : 2.51 (-7.38%)
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AGLE : 12.01 (+8.79%)
HUMA : 3.60 (+0.28%)
Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 7.34 (-2.78%)
HUMA : 3.60 (+0.28%)
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

MCRB : 0.5501 (-5.84%)
HUMA : 3.60 (+0.28%)
Humacyte (HUMA) Completes Enrollment in HAV Technology Study

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.

CRSP : 54.80 (-2.42%)
KALA : 6.65 (-2.35%)
ALLO : 3.41 (-1.45%)
HUMA : 3.60 (+0.28%)
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HUMA : 3.60 (+0.28%)
SYBX : 1.8900 (+3.28%)
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

HOWL : 5.89 (+0.34%)
HUMA : 3.60 (+0.28%)
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

URGN : 13.18 (-7.57%)
HUMA : 3.60 (+0.28%)
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 8.75 (+0.92%)
HUMA : 3.60 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 4.42
2nd Resistance Point 4.08
1st Resistance Point 3.84
Last Price 3.60
1st Support Level 3.26
2nd Support Level 2.92
3rd Support Level 2.68

See More

52-Week High 5.60
Fibonacci 61.8% 4.21
Fibonacci 50% 3.78
Last Price 3.60
Fibonacci 38.2% 3.35
52-Week Low 1.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar